Form 4: Adaptive Biotechnologies' Chief People Officer, Francis Lo, Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Francis Lo, Chief People Officer of Adaptive Biotechnologies, reports the acquisition and disposal of company stock and stock options related to vesting RSUs and tax obligations.

Summary

  • On March 4, 2024, Francis Lo, Chief People Officer of Adaptive Biotechnologies, acquired 99,976 shares of common stock at $0.
  • On March 5, 2024, Lo sold 12,887 shares at $3.43 and 1,813 shares at $3.44 to cover tax withholding obligations related to vesting RSUs.
  • Following these transactions, Lo directly owns 253,745 shares of common stock and indirectly owns 2,500 shares through You Jin Lee (spouse).
  • Lo also acquired options to purchase 150,024 shares of common stock at an exercise price of $3.99, vesting in installments starting March 4, 2025, and expiring on March 4, 2034.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive; it doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in company stock.

Key Dates

DateDescription
03/04/2024Date of common stock acquisition and stock option grant.
03/05/2024Date of common stock sales to cover tax obligations.
03/04/2025First vesting date for stock options.
03/04/2034Expiration date for stock options.
03/06/2024Date of Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.